Page last updated: 2024-11-05

3-chlorophenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-chlorophenol : A monochlorophenol carrying the chloro substituent at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7933
CHEMBL ID41172
CHEBI ID38855
SCHEMBL ID49772
MeSH IDM0096866

Synonyms (65)

Synonym
phenol, m-chloro-
nsc59700
nsc-59700
3-hydroxychlorobenzene
m-chlorophenol
wln: qr cg
3-chlorophenol
inchi=1/c6h5clo/c7-5-2-1-3-6(8)4-5/h1-4,8
108-43-0
phenol, 3-chloro-
3CH ,
NCGC00091698-01
einecs 203-582-6
nsc 59700
m-chlorophenic acid
ai3-23961
ccris 641
3-chloro-1-hydroxybenzene
hsdb 1413
3-chlorophenol, 98%
DB01957
1LI3
CHEBI:38855 ,
meta-chlorophenol
3-chloro-phenol
CHEMBL41172 ,
AKOS000118748
bdbm50167952
NCGC00091698-02
25231-12-3
dtxcid004800
dtxsid4024800 ,
NCGC00258387-01
tox21_200833
cas-108-43-0
m-chlorophenol, liquid [un2021] [keep away from food]
z2z7m2ftad ,
m-chlorophenol, solid [un2020] [keep away from food]
unii-z2z7m2ftad
m-chlorophenol, liquid
m-chlorophenol, solid
FT-0615504
PS-6042
chlorophenol, m-
3-chlorophenol [hsdb]
m-chlorophenol [mi]
SCHEMBL49772
3-chloro phenol
m-chloro-phenol
un 2021 (salt/mix)
un 2020 (salt/mix)
CS-W020573
W-108718
mfcd00002256
F0001-0169
3-chlorophenol, pestanal(r), analytical standard
3-chlorophenol 100 microg/ml in methanol
Q3973362
3-cyclohexyl-2-thioxotetrahydropyrimidin-4(1h)-one
AMY10409
STL183823
D95297
EN300-19378
PD008270
Z104473668

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Binary mixture tests were conducted using proportions of the respective IC50s in terms of toxic unit (TU)."( Single and mixture toxicity of pharmaceuticals and chlorophenols to freshwater algae Chlorella vulgaris.
Geiger, E; Hornek-Gausterer, R; Saçan, MT, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" The maximum toxicity normally occurred before the maximum color intensity was monitored, while ozone dosage applied was within 1 mg of ozone per mg of initial CPs."( Variation of toxicity during the ozonation of monochlorophenolic solutions.
Ma, HW; Shang, NC; Yu, YH, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monochlorophenol
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
chlorinated phenols degradation110

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thyroid stimulating hormone receptorHomo sapiens (human)Potency1.58490.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency60.38530.000657.913322,387.1992AID1259377
pregnane X nuclear receptorHomo sapiens (human)Potency30.26440.005428.02631,258.9301AID1346982
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency43.129119.739145.978464.9432AID1159509
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency53.08040.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)457.08800.00101.979414.1600AID255211
Oxysterols receptor LXR-betaHomo sapiens (human)Ki184.00000.00220.07300.3520AID1562690
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, LysozymeTequatrovirus T4Kd56.000056.000082.3333100.0000AID977611
Chain A, LysozymeTequatrovirus T4Kd56.000056.000082.3333100.0000AID977611
Chain A, LysozymeTequatrovirus T4Kd56.000056.000082.3333100.0000AID977611
Chain A, LysozymeTequatrovirus T4Kd56.000056.000082.3333100.0000AID977611
EndolysinTequatrovirus T4Kd56.00003.00003.00003.0000AID238123
Oxysterols receptor LXR-betaHomo sapiens (human)EC50 (µMol)519.00000.00010.40077.3000AID1562693
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (29)

Processvia Protein(s)Taxonomy
hormone-mediated signaling pathwayOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of triglyceride biosynthetic processOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of cholesterol effluxOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of lipid storageOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of cholesterol storageOxysterols receptor LXR-betaHomo sapiens (human)
intracellular receptor signaling pathwayOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of lipid transportOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of cholesterol transportOxysterols receptor LXR-betaHomo sapiens (human)
phosphatidylcholine acyl-chain remodelingOxysterols receptor LXR-betaHomo sapiens (human)
cholesterol homeostasisOxysterols receptor LXR-betaHomo sapiens (human)
mRNA transcription by RNA polymerase IIOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of fatty acid biosynthetic processOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of proteolysisOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of DNA-templated transcriptionOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of pinocytosisOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of lipoprotein lipase activityOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of protein metabolic processOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of high-density lipoprotein particle assemblyOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of pancreatic juice secretionOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of secretion of lysosomal enzymesOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of cold-induced thermogenesisOxysterols receptor LXR-betaHomo sapiens (human)
positive regulation of miRNA transcriptionOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressOxysterols receptor LXR-betaHomo sapiens (human)
cell differentiationOxysterols receptor LXR-betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIOxysterols receptor LXR-betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingOxysterols receptor LXR-betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificOxysterols receptor LXR-betaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificOxysterols receptor LXR-betaHomo sapiens (human)
DNA bindingOxysterols receptor LXR-betaHomo sapiens (human)
protein bindingOxysterols receptor LXR-betaHomo sapiens (human)
zinc ion bindingOxysterols receptor LXR-betaHomo sapiens (human)
chromatin DNA bindingOxysterols receptor LXR-betaHomo sapiens (human)
apolipoprotein A-I receptor bindingOxysterols receptor LXR-betaHomo sapiens (human)
nuclear retinoid X receptor bindingOxysterols receptor LXR-betaHomo sapiens (human)
ATPase bindingOxysterols receptor LXR-betaHomo sapiens (human)
nuclear receptor activityOxysterols receptor LXR-betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
nucleusOxysterols receptor LXR-betaHomo sapiens (human)
nucleoplasmOxysterols receptor LXR-betaHomo sapiens (human)
cytoplasmOxysterols receptor LXR-betaHomo sapiens (human)
cytosolOxysterols receptor LXR-betaHomo sapiens (human)
RNA polymerase II transcription regulator complexOxysterols receptor LXR-betaHomo sapiens (human)
chromatinOxysterols receptor LXR-betaHomo sapiens (human)
nucleusOxysterols receptor LXR-betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1562693Agonist activity at recombinant human LXRbeta-LBD expressed in Escherichia coli BL21 (DE3) assessed as peptide D22 recruitment fluorescence polarization binding assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Identify liver X receptor β modulator building blocks by developing a fluorescence polarization-based competition assay.
AID19427HPLC capacity factor (k)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID29421Partition coefficient (logP) (HPLC)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID28957Partition coefficient (logP)2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Rational determination of transfer free energies of small drugs across the water-oil interface.
AID1562692Competitive binding affinity to recombinant human LXRbeta-LBD expressed in Escherichia coli BL21 (DE3) at 1 mM incubated for 30 mins by fluorescence polarization binding assay relative to tracer 12019European journal of medicinal chemistry, Sep-15, Volume: 178Identify liver X receptor β modulator building blocks by developing a fluorescence polarization-based competition assay.
AID282834Activity against caspase-mediated apoptosis in mouse L1210 cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID27580Partition coefficient (logP)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID1562694Agonist activity at recombinant human LXRbeta-LBD expressed in human HEK293T cells incubated for 20 hrs by luciferase reporter gene assay relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178Identify liver X receptor β modulator building blocks by developing a fluorescence polarization-based competition assay.
AID282833Activity against caspase-mediated apoptosis in mouse L1210 cells at 0.1 mM2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID1562690Binding affinity to recombinant human LXRbeta-LBD expressed in Escherichia coli BL21 (DE3) assessed as inhibitory constant incubated for 30 mins by fluorescence polarization binding assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Identify liver X receptor β modulator building blocks by developing a fluorescence polarization-based competition assay.
AID1134600Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID282835Cytotoxicity against mouse L1210 cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID28956Partition coefficient (logP) (dodecane)2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Rational determination of transfer free energies of small drugs across the water-oil interface.
AID23978Capacity ratio (log k'w)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID203473Binding constant against bovine serum albumin1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID238123Dissociation constant against T4 lysozyme mutant L99A/M102Q2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Decoys for docking.
AID1134603Oleyl alcohol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID23714Partition coefficient (logP)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID361985Lipophilicity, log D of compound at pH 7.4 by microfluidic liquid-liquid extraction method2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Determination of log D via automated microfluidic liquid-liquid extraction.
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID361986Lipophilicity, log D of compound at pH 7.4 by shake flask method2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Determination of log D via automated microfluidic liquid-liquid extraction.
AID1811Experimentally measured binding affinity data derived from PDB2002Journal of molecular biology, Sep-13, Volume: 322, Issue:2
A model binding site for testing scoring functions in molecular docking.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2002Journal of molecular biology, Sep-13, Volume: 322, Issue:2
A model binding site for testing scoring functions in molecular docking.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (5.77)18.7374
1990's6 (11.54)18.2507
2000's26 (50.00)29.6817
2010's17 (32.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.62 (24.57)
Research Supply Index3.99 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index63.24 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.89%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (98.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]